文献速递眼底病与葡萄膜炎

生物制剂治疗葡萄膜炎患者合并COVID-19感染的影响

Implications of COVID-19 infection on patients with uveitis under biologic treatment.
PubMed 文献 · Br J Ophthalmol · 2021-04-30

9例(15.3%)COVID-19检测阳性,随访期间均未出现COVID-19相关症状;9例阳性患者中仅2例在停用生物制剂后出现葡萄膜炎复发。结论提示接受生物制剂治疗的葡萄膜炎患者可能是COVID-19的无症状携带者。

要点

  • 接受生物制剂治疗的葡萄膜炎患者中COVID-19检测阳性率为15.3%(9/59)。
  • 9例COVID-19阳性患者随访期间均未出现COVID-19相关症状。
  • 9例阳性患者中仅2例在停用生物制剂后出现葡萄膜炎复发。

核心结论

  • 接受生物制剂治疗的葡萄膜炎患者可能是COVID-19的无症状携带者。

主要发现

  • 白塞病为最常见诊断(64.4%),英夫利西单抗为最常用生物制剂(61%)。
  • 9例(15.3%)患者COVID-19检测阳性。
  • 所有COVID-19阳性患者在随访期间均未出现COVID-19相关症状。
  • 9例COVID-19阳性患者中,仅2例在停用生物制剂后出现葡萄膜炎复发。

临床怎么用

  • 接受生物制剂治疗的葡萄膜炎患者可能为COVID-19无症状携带者,临床需关注其潜在传播风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic. METHODS: In this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020. RESULTS: A total of 59 patients were identified. Behçet's disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension. CONCLUSION: Uveitis patients under biologic therapy can be silent carriers for COVID-19.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. AlBloushi AF, Alfawaz AM, Abu El Asrar AM, et al. Implications of COVID-19 infection on patients with uveitis under biologic treatment. Br J Ophthalmol. 2021. PMID: 33931386. doi:10.1136/bjophthalmol-2020-318577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。